2026-08-29T17:24:53Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/187242025-03-20T10:51:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16938col_20.500.12105_16927

00925njm 22002777a 4500 dc Villanego, Florentino author Mazuecos, Auxiliadora author Cubillo, Beatriz author Merino, M José author Poveda, Inmaculada author Saura, Isabel M author Segurado, Óscar author Cruzado, Leónidas author Eady, Myriam author Zárraga, Sofía author Aladrén, María José author Cabello, Sheila author López, Verónica author González, Esther author Lorenzo, Inmaculada author Espí-Reig, Jordi author Fernández, Constantino author Osma, July author Ruiz-Fuentes, M Carmen author Toapanta, Néstor author Franco, Antonio author Burballa, Carla C author Muñoz, Miguel A author Crespo, Marta author Pascual, Julio author 2022-07-28 Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The evidence on its use in kidney transplant (KT) recipients, however, is limited. We performed a multicenter, retrospective cohort study of 82 KT patients with SARS-CoV-2 infection {coronavirus disease 2019 [COVID-19]} treated with sotrovimab. Median age was 63 years. Diabetes was present in 43.9% of patients, and obesity in 32.9% of patients; 48.8% of patients had an estimated glomerular filtration rate under 30 mL/minute/1.73 m2. Additional anti-COVID-19 therapies were administered to 56 patients, especially intravenous steroids (65.9%). Sotrovimab was administered early ( Sotrovimab had an excellent safety profile, even in high-comorbidity patients and advanced chronic kidney disease stages. Earlier administration could prevent progression to severe disease, while clinical outcomes were poor in patients treated later. Larger controlled studies enrolling KT recipients are warranted to elucidate the true efficacy of monoclonal antibody therapies. 10.1093/ckj/sfac177 2048-8505 Clinical kidney journal http://hdl.handle.net/10668/19754 36147706 http://hdl.handle.net/20.500.12105/18724 COVID-19 immunosuppression kidney transplantation monoclonal antibodies mortality Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients.